                         SEQUENCE LISTING

<110>  Eli Lilly and Company
       Zhang, Lianshan
       Alsina-Fernandez, Jorge

<120>  Selective VPAC2 Receptor Peptide Agonists

<130>  X17364 WO

<150>  US 60/743,366
<151>  2006-02-28

<160>  8     

<170>  PatentIn version 3.3

<210>  1
<211>  32
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: VPAC2 receptor peptide agonist

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa may be present or absent. If present, Xaa is His or dH

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is dA, Ser, Val, Gly, Thr, Leu, dS, Pro, or Aib

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Asp or Glu

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is Ala, Ile, Tyr, Phe, Val, Thr, Leu, Trp, Gly, dA, Aib, or NMeA

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Val, Leu, Phe, Ile, Thr, Trp, Tyr, dV, Aib, or NMeV

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is Phe, Ile, Leu, Thr, Val, Trp, or Tyr

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is Asp, Glu, Ala, Lys, Leu, Arg, or Tyr

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is Asn, Gln, Glu, Ser, Cys, or K(CO(CH2)2SH)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is Tyr, Trp, or Tyr(OMe)

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa is Arg, Lys, hR, Orn, Aib, Ala, Leu, Gln, Phe, or Cys

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is Leu, Phe, Glu, Ala, Aib, Ser, Cys, or K(CO(CH2)2SH)

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is Arg, Leu, Lys, Ala, hR, Orn, Phe, Gln, Aib, or Cit

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa is Lys, Ala, Arg, Glu, Leu, Orn, Phe, Gln, Aib, K(Ac), Cys, K(W), or K(CO(CH2)2SH)

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is Gln, Lys, Ala, Ser, Cys, or K(CO(CH2)2SH)

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is Val, Ala, Leu, Ile, Met, Nle, Lys, Aib, Ser, Cys, K(CO(CH2)2SH), or K(W)

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  Xaa is Ala, Ser, Cys, or Abu

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  Xaa is Ala, Leu, Gly, Ser, Cys, K(CO(CH2)2SH), or Abu

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is Lys, Gln, hR, Arg, Ser, Orn, Ala, Aib, Trp, Thr, Leu, Ile, Phe, Tyr, Val, K(Ac), Cys, or K(CO(CH2)2SH)

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  Xaa is Lys, Arg, Ala, Phe, Aib, Leu, Gln, Orn, hR, K(Ac), Ser, Cys, K(W), K(CO(CH2)2SH), or hC

<220>
<221>  MISC_FEATURE
<222>  (22)..(22)
<223>  Xaa is Tyr, Trp, Phe, Thr, Leu, Ile, Val, Tyr(OMe), Ala, Aib, or Ser 

<220>
<221>  MISC_FEATURE
<222>  (23)..(23)
<223>  Xaa is Leu, Phe, Ile, Ala, Trp, Thr, Val, Aib, or Ser

<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  Xaa is Gln, Asn, Ser, Cys, K(CO(CH2)2SH), or K(W)

<220>
<221>  MISC_FEATURE
<222>  (25)..(25)
<223>  Xaa is Ser, Asp, Phe, Ile, Leu, Thr, Val, Trp, Gln, Asn, Tyr, Aib, Glu, Cys, K(CO(CH2)2SH), or hC

<220>
<221>  MISC_FEATURE
<222>  (26)..(26)
<223>  Xaa is Ile, Leu, Thr, Val, Trp, Tyr, Phe, Aib, Ser, Cys, K(CO(CH2)2SH), or K(W)

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa is Lys, hR, Arg, Gln, Orn, or dK 

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is Asn, Gln, Lys, Arg, Aib, Orn, hR, Pro, dK, Cys, K(CO(CH2)2SH), or K(W) 

<220>
<221>  MISC_FEATURE
<222>  (29)..(32)
<223>  Any Xaa may be present or absent. If any Xaa is absent, the next 
       amino acid present downstream is the next amino acid in the 
       peptide agonist sequence

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa may be present or absent. If present, Xaa is Lys, Ser, Arg, Asn, hR, Cys, or Orn 

<220>
<221>  MISC_FEATURE
<222>  (30)..(30)
<223>  Xaa may be present or absent. If present, Xaa is Arg, Lys, Ile, or hR 

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa may be present or absent. If present, Xaa is Tyr, His, Phe, or Gln 

<220>
<221>  MISC_FEATURE
<222>  (32)..(32)
<223>  Xaa may be present or absent. If present, Xaa is Cys

<400>  1

Xaa Xaa Xaa Xaa Xaa Xaa Thr Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
            20                  25                  30          


<210>  2
<211>  32
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: VPAC2 receptor peptide agonist


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Asp or Glu 

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is Asp, Glu, Ala, Lys, Leu, Arg, or Tyr 

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is Asn, Gln, Glu, Ser, Cys, or K(CO(CH2)2SH) 

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is Tyr, Trp, or Tyr(OMe) 

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa is Arg, Lys, hR, Orn, Aib, Ala, Leu, Gln, Phe, or Cys 

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is Leu, Phe, Glu, Ala, Aib, Ser, Cys, or K(CO(CH2)2SH) 

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is Arg, Leu, Lys, Ala, hR, Orn, Phe, Gln, Aib, or Cit 

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa is Lys, Ala, Arg, Glu, Leu, Orn, Phe, Gln, Aib, K(Ac), Cys, K(W), or K(CO(CH2)2SH 

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is Gln, Lys, Ala, Ser, Cys, or K(CO(CH2)2SH) 

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is Val, Ala, Leu, Ile, Met, Nle, Lys, Aib, Ser, Cys, K(CO(CH2)2SH), or K(W) 

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  Xaa is Ala, Ser, Cys, or Abu 

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  Xaa is Ala, Leu, Gly, Ser, Cys, K(CO(CH2)2SH), or Abu 

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is Lys, Gln, hR, Arg, Ser, Orn, Ala, Aib, Trp, Thr, Leu, Ile, Phe, Tyr, Val, K(Ac), Cys, or K(CO(CH2)2SH) 

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  Xaa is Lys, Arg, Ala, Phe, Aib, Leu, Gln, Orn, hR, K(Ac), Ser, Cys, K(W), K(CO(CH2)2SH), or hC 

<220>
<221>  MISC_FEATURE
<222>  (22)..(22)
<223>  Xaa is Tyr, Trp, Phe, Thr, Leu, Ile, Val, Tyr(OMe), Ala, Aib, or Ser 

<220>
<221>  MISC_FEATURE
<222>  (23)..(23)
<223>  Xaa is Leu, Phe, Ile, Ala, Trp, Thr, Val, Aib, or Ser 

<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  Xaa is Gln, Asn, Ser, Cys, K(CO(CH2)2SH), or K(W) 

<220>
<221>  MISC_FEATURE
<222>  (25)..(25)
<223>  Xaa is Ser, Asp, Phe, Ile, Leu, Thr, Val, Trp, Gln, Asn, Tyr, Aib, Glu, Cys, K(CO(CH2)2SH), or hC 

<220>
<221>  MISC_FEATURE
<222>  (26)..(26)
<223>  Xaa is Ile, Leu, Thr, Val, Trp, Tyr, Phe, Aib, Ser, Cys, K(CO(CH2)2SH), or K(W) 

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa is Lys, hR, Arg, Gln, Orn, or dK 

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is Asn, Gln, Lys, Arg, Aib, Orn, hR, Pro, dK, Cys, K(CO(CH2)2SH), or K(W) 

<220>
<221>  MISC_FEATURE
<222>  (29)..(32)
<223>  Any Xaa may be present or absent. If any Xaa is absent, the next 
       amino acid present downstream is the next amino acid in the 
       peptide agonist sequence

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa may be present or absent. If present, Xaa is Lys, Ser, Arg, Asn, hR, Cys, or Orn 

<220>
<221>  MISC_FEATURE
<222>  (30)..(30)
<223>  Xaa may be present or absent. If present, Xaa is Arg, Lys, Ile, or hR 

<220>
<221>  MISC_FEATURE
<222>  (31)..(31)
<223>  Xaa may be present or absent. If present, Xaa is Tyr, His, Phe, or Gln 

<220>
<221>  MISC_FEATURE
<222>  (32)..(32)
<223>  Xaa may be present or absent. If present, Xaa is Cys

<400>  2

His Ser Xaa Ala Val Phe Thr Xaa Xaa Xaa Thr Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
            20                  25                  30          


<210>  3
<211>  28
<212>  PRT
<213>  Homo sapiens

<400>  3

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn 
            20                  25              


<210>  4
<211>  27
<212>  PRT
<213>  Homo sapiens

<220>
<221>  MOD_RES
<222>  (27)..(27)
<223>  AMIDATION

<400>  4

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu 
            20                  25          


<210>  5
<211>  37
<212>  PRT
<213>  Homo sapiens

<220>
<221>  MOD_RES
<222>  (37)..(37)
<223>  AMIDATION

<400>  5

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Gln 
            20                  25                  30          


Arg Val Lys Asn Lys 
        35          


<210>  6
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: N-terminal modification to a VPAC2 receptor 
       agonist wherein the Arg at position 9 is linked to the N-terminus
       of the peptide agonist

<400>  6

Ser Trp Cys Glu Pro Gly Trp Cys Arg 
1               5                   


<210>  7
<211>  39
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: VPAC2 receptor peptide agonist P603

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  C6 acylation

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Methoxy

<220>
<221>  MOD_RES
<222>  (12)..(12)
<223>  Orn

<220>
<221>  MOD_RES
<222>  (15)..(15)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (19)..(19)
<223>  Abu

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (21)..(21)
<223>  Orn

<220>
<221>  MOD_RES
<222>  (23)..(23)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (25)..(25)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (27)..(28)
<223>  Orn

<220>
<221>  MOD_RES
<222>  (39)..(39)
<223>  C-terminal lysine residue has a glutamic acid residue, which is 
       acylated at the alpha-amino group with palmitic acid, attached to
       its side chain

<220>
<221>  MOD_RES
<222>  (39)..(39)
<223>  AMIDATION

<400>  7

His Ser Asp Ala Val Phe Thr Glu Gln Tyr Thr Xaa Leu Arg Xaa Gln 
1               5                   10                  15      


Leu Ala Xaa Xaa Xaa Tyr Xaa Gln Xaa Ile Xaa Xaa Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Lys 
        35                  


<210>  8
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: C-terminal extension of a VPAC2 receptor 
       peptide agonist

<220>
<223>  C-terminal amino acid may be amidated

<220>
<221>  MOD_RES
<222>  (11)..(11)
<223>  C-terminal lysine residue has a glutamic acid residue, which is 
       acylated at the alpha-amino group with palmitic acid, attached to
       its side chain

<400>  8

Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Lys 
1               5                   10      


